Compositions and methods for weight loss in at risk patient populations
TW201446247A
Methods of treating overweight and obesity
KR20210012056A
Methods of treating overweight and obesity
RS56014B1
Increasing drug bioavailability in naltrexone therapy
BR112012016783A2
"Uses of the naltrexone compound or pharmaceutically acceptable salt thereof to bupropion or pharmaceutically acceptable salt thereof or composition thereof and methods for providing therapy"
CA2725930A1
Methods for treating visceral fat conditions
KR20190042766A
Layered pharmaceutical formulations comprising an intermediate rapidly dissolving layer
CA2668885A1
Methods for administering weight loss medications
US2007185084A1
Compositions of an anticonvulsant and methods of using the same for reversing weight gain
US2007148237A1
Sustained-release formulation of zonisamide
TW200803901A
Methods of treating anxiety disorders
WO2007089318A2
Compositions and methods for reducing food cravings
BRPI0613911A2
compositions to affect weight loss
KR20080021046A
Methods and compositions for managing psychotic disorders
WO2006088748A2
Method for treating obesity
KR20070083534A
Combination of bupropion and a second compound for affecting weight loss
WO2005107806A1
Compositions for affecting weight loss
EP1870096A2
Compositions for affecting weight loss
EP2316456A1
Compositions for affecting weight loss comprising an opioid antagonist and bupropion
